José Carlos Jaime‐Pérez

ORCID: 0000-0001-6804-9095 · 1 paper in corpus

other 2017

Danazol as First-Line Therapy for Myelodysplastic Syndrome

Clinical lymphoma, myeloma & leukemia ·doi:10.1016/j.clml.2017.11.007

BACKGROUND: Allogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic…